Skip to main content
23andMe
Therapeutics

Turning discoveries into therapies

Here’s what’s in our Pipeline:

  • Immuno-oncology CD200R1
  • Immuno-oncology CD96
  • Immuno-oncology *
  • Cardiovascular / Metabolic*
  • Immunology*
  • Neurology*

*40+ programs in the combined therapeutic areas. As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets.

Our current clinical programs

CD200R1

This 23andMe-owned immuno-oncology program is currently in Phase 1 in patients with advanced solid tumors (NCT05199272).

CD96

This immuno-oncology program with GSK is currently in Phase 1 in patients with advanced solid tumors (NCT04446351).